anti-ErbB3 bi-specific mAbs/antibody nanoparticle conjugates (Immune/Yeda)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-ErbB3 bi-specific mAbs/antibody nanoparticle conjugates (Immune/Yeda)
Drug Alias Nameanti-ErbB3 bi-specific mAbs (Immune Pharmaceuticals)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonists
TargetsReceptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesImmune Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesYeda Research and Development Co LtdImmune Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A